FDA Settles Allegations Of Uneven Blood Treatment Standards

By Ruben Castaneda · February 8, 2024, 8:32 PM EST

The U.S. Food and Drug Administration has settled a pharmaceutical company's lawsuit in D.C. federal court accusing the agency of subjecting the company's blood-clotting medication to costly clinical trials and higher...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Motion

Case Information

Case Title

OCTAPHARMA USA, INC. et al v. BECERRA et al

Case Number

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Date Filed

September 14, 2022

Recent Articles By Ruben

February 13, 2024
Insurers Must Pay Pharma Co. Defense Costs In SEC Probe
February 06, 2024
Sheppard Mullin Adds Partner From Faegre Drinker In Chicago
February 05, 2024
Tennessee Asks Justices To Keep Gender-Affirming Care Ban
January 31, 2024
FDA May Have To Cut Activities As Need to Regulate AI Grows
January 19, 2024
Ohio Court Blesses Atty's 'Zealous' Strategy, Axes Sanctions
January 05, 2024
NJ Brothers Ordered To Prison For Prescription Drug Scheme
January 04, 2024
Hospital Network Told To Provide Contracts In Antitrust Suit
December 20, 2023
Medical Device Cos. Settle Trade Secrets Suit For $8M
December 19, 2023
Anesthesiologists Say CMS Reimbursement Math Is Unlawful
December 15, 2023
Ky. Hospital Didn't Do Enough To Stop Data Breach, Suit Says